DocumentsDate added
Research article
Suresh V Dange1, Shrikrishna Subhash Shende2*,Balchandra T Rane3,Abhijeet V Tilak4,Moh anish U Vaidya2,Manasi V Limaye2
1 MBBS, MD Pharmacology, DNB Family Medicine, Department of Pharmacology,Dr. D.Y. Patil Medical College, Pimpri, Pune,411018, India
2 MBBS MD, Junior Resident, Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune, 411018, India
3 MBBS, Department of Pharmacology,Dr. D.Y. Patil Medical College, Pimpri,Pune, 411018, India
4 MBBS, MD Pharmacology, Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune, 411018, India
Address reprint requests to
*Dr. Shrikrishna Subhash Shende,
Department of Pharmacology, Dr. D.Y. Patil Medical College, Pimpri, Pune 411018, India
Article citation: Dange SV, Shende SS,Rane BT, Tilak AV, Vaidya MU, Limaye MV. An observational study of the antidiabetic activity of berberine in newly diagnosed type 2 diabetes mellitus patients. J Pharm Biomed Sci 2016;06(03):230–233. Available at www.jpbms.info
Abstract:
Background Suboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to achieve glycemic targets. There is in fact a growing body of literature on plants used for the treatment of diabetes. In this respect, in the past few years, attempts were made to use natural plant products for the treatment of patients with diabetes.
Berberine is a commonly available as a nutraceutical and it is a potential candidate for diabetes. Methods and Results A total of 30 newly diagnosed type 2 diabetes mellitus patients
were included in the study after obtaining their informed written consent. They were divided into two groups (n = 15 each), receiving either metformin 500 mg/12 h or berberine 500 mg/12 h p.o. for 12 weeks. No other antidiabetic drugs were given. Therapeutic life style measures were common in both groups. Physical examination and estimation of laboratory parameters were done at baseline and after 12 weeks. Laboratory parameters estimated were fasting blood glucose level (FBG), post prandial blood glucose level (PPBG), glycated hemoglobin (GHb), lipid profile, serum alanine transferase and serum creatinine. Berberine treatment significantly reduced FBG, PPBG, GHb levels and there was significant improvement in lipid profile. The results were comparable to those with metformin.
Conclusion Berberine (500 mg twice daily) may be a useful antidiabetic drug.
KEYWORDS antidiabetic activity, berberine, type 2 diabetes mellitus.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Acknowledgement: The free samples of berberine (Berbeshine hydrochloride 500 mg) were provided by Akumentis Healthcare Ltd, Mumbai.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
REFERENCES
1.Ni YX. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi. 1988;8:711–713.
2.Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294:E148–E156.
3.Xie P, Zhou H, Gao Y. The clinical efficacy of berberine in treatment of type 2 diabetes mellitus [article in Chinese]. Chin J Clin Healthcare. 2005;8:402–403.
4.Wei J, Wu J, Jiang J, Wang S, Wang Z. Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine [article in Chinese]. Zhong Xi Yi Jie He Ganbing Za Zhi. 2004;14:334–336.
5.Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes. Metabolism. 2008;57(5):712–717.
6.Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, et al. Metaanalysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81.
7.Zhang Y, Li Y, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–2565.
8.Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine,a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–2264.
9.Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism. 2007;56:405–412.
10.Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002;51:1439–1443.
11.Yin J, Chen M, Tang J, Li F, Zhou L, Yang Y, et al. Effects of berberine on glucose and lipid metabolism in animal experiment. Chin J Diabetes. 2004;12:215–218.
12.Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine,a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes.2006;55:2256–2264.
Original article
Ting-Mei Wang1,Yi-Fang Li1,Hiroshi Kurihara1,2,Rong-Rong He1*
1 Anti-Stress and Health Research Center,College of Pharmacy, Jinan University, Guangzhou, China
2 Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou, China
Address reprint requests to
*Rong-Rong He, PhD, Institute of Traditional Chinese Medicine and Natural Products, Jinan University,Guangzhou, China
Article citation: Wang TM, Li YF, Kurihara H, He RR. Toxicity induced by Madopar (l-DOPA) during curing Parkinson’s disease by inhibiting mitochondrial function and AKT pathway. J Pharm Biomed Sci 2016;06(03):250–254.Available at www.jpbms.info
ABSTRACT
Complexity myelofibrosis diagnosis at an early stage is that it takes place under other conditions mask: anaemia, abdominal pain, enlarged liver and spleen. This article describes
a case of myelofibrosis in a child, when the diagnosis was made late, which resulted in a poor prognosis.
KEYWORDS myelofibrosis, myeloproliferative disorders, acute myeloid leukemia
REFERENCES
1.Dagur G, Warren K, Schwamb R, Dalpiaz A, Gandhi J, Khan S.Neuro-urological manifestations of Parkinson’s disease. Int J Neurosci. 2016;126:481–487.
2.Lindholm D, Mäkelä J, Di Liberto V, Mudo G, Belluardo N,Eriksson O, et al. Current disease modifying approaches to treat Parkinson’s disease. Cell Mol Life Sci. 2016;73:1365–79.
3.Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–144.
4.Ishida Y, Ebihara K, Tabuchi M, Imamura S, Sekiguchi K,Mizoguchi K, et al. Yokukansan, a traditional Japanese medicine, enhances the l-DOPA-induced rotational response in 6-hydroxydopamine-lesioned rats: possible inhibition of COMT. Biol Pharm Bull. 2016;39:104–113.
5.Ghiglieri V, Mineo D, Vannelli A, Cacace F, Mancini M, Pendolino V, et al. Modulation of serotonergic transmission by eltoprazine in l-DOPA-induced dyskinesia: behavioral, molecular, and synaptic mechanisms. Neurobiol Dis. 2016;86:140–153.
6.Park KH, Shin KS, Zhao TT, Park HJ, Lee KE, Lee MK. l-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells. Neuropharmacology. 2016;101:87–97.
7.Nikolaus S, Beu M, de Souza Silva MA, Huston JP, Hautzel H,Mattern C, et al. Relationship between l-DOPA-induced reduction in motor and exploratory activity and striatal dopamine D-2 receptor binding in the rat. Front Behav Neurosci. 2016;10:36.
8.Jang W, Park HH, Lee, KY, Lee YJ, Kim HT, Koh SH. 1,25-dyhydroxyvitamin D-3 attenuates l-DOPA-induced neurotoxicity in neural stem cells. Mol Neurobiol. 2015;51:558–570.
9.Lanzillotta A, Porrini V, Bellucci A, Benarese M, Branca C, Parrella E, et al. NF-kappa B in innate neuroprotection and age-related neurodegenerative diseases. Front Neurol. 2015;6:98.
10.Gangarossa G, Guzman M, Prado VF, Prado MAM, Daumas S, El Mestikawy S, et al. Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia. Neurobiol Dis. 2016;87:69–79.
11.Park HY, Ryu YK, Kim YH, Park TS, Go J, Hwang JH, et al. Gadd45β ameliorates l-DOPA-induced dyskinesia in a Parkinson’s disease mouse model. Neurobiol Dis. 2016;89:169–79.
12.Mu X, Yuan X, Du LD, He GR, Du GH. Antagonism of quercetin against tremor induced by unilateral striatal lesion of 6-OHDA in rats. J Asian Nat Prod Res. 2016;18:65–71.
13.Zhang X, Li Y, Liu C, Fan R, Wang P, Zheng L, et al. Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson’s disease rats. Transl Res. 2015;166:152–162.
14.Yu ZH, Cai M, Xiang J, Zhang ZN, Zhang JS, Song XL, et al.PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats. J Ethnopharmacol. 2016;181:8–19.
15.Feng X, Wu C, Yang M, Liu Q, Li H, Liu J, et al. Role of PI3K/Akt signal pathway on proliferation of mesangial cell induced by HMGB1. Tissue Cell. 2016;48:121–5.
16.Bove J, Martinez-Vicente M, Dehay B, Perier C, Recasens A, Bombrun A, et al. BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy. 2014;10:889–900.
17.Rekha KR, Selvakumar GP. Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/ probenecid induced C57BL/6 mice model of Parkinson’s disease. Chem Biol Interact. 2014;217:57–66.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript. The first two authors contributed equally to the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Original article
Wen-Shan Huang1,Yi-Fang Li1,Huan Chen1,Ting-Mei Wang1,Hiroshi Kurihara1,2, Rong-Rong He1,2*
1Anti-Stress and Health Research center,College of Pharmacy, Jinan University, Guangzhou, China
2Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou, China
Address reprint requests to
*Rong-Rong He,
Anti-Stress and Health Research center, College of Pharmacy,Jinan University, Guangzhou, China
Article citation: Huang WS, Li YF, Chen H, Wang TM, Kurihara H, He RR. The ameliorative effects of CE (a chicken extract) on learning and memory function of restraint-stressed mice. J Pharm Biomed Sci 2016;06(03):259–263. Available at www.jpbms.info
ABSTRACT
In this study, we studied the effects of Chicken Essence (CE) on learning and memory function of restraint-stressed mice. Male Kunming mice of 7-week-old were randomly divided into five groups as follows: normal control, restraint stress control, low dosage of CE (12 ml/kg/d, CE-L) and high dosage of CE (24 ml/kg/d, CE-H). The normal control group and restrain stress control group received water only. On the 14th day of administration,all mice were conducted to step through training, and physically restrained
in a 50 ml restrained tube with holes for 18 h except for normal control mice. All mice were conducted to step through testing, 1 day after restraint stress. All animals were anesthetized, their brains and blood were obtained. We determined the neuron protective transmitters, dopamine hydrochloride and norepinephrine level in brain and plasma via ESA–HPLC. The results showed that the administration of CE could improve the impaired function of learning and memory. Furthermore, it also recovered the changed levels of neurotransmitters in brain or plasma in restraint-stressed mice.
Keywords learning and memory; restraint stress; stress hormone
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
ORIGINAL ARTICLE
Huan Chen1,2,Yi-Fang Li1,Chong Jie1,Hiroshi Kurihara1,2,Rong-Rong He1*
1Institute of Traditional Chinese Medicine and Natural Products, Jinan University,Guangzhou, China
2 Changsha Medical University, Changsha,China
Address reprint requests to
*Rong-Rong He, Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou, China
Article citation: Chen H, Li YF, Jie C,Kurihara H, He RR. Effects of chicken extract on 5-HT level in mice loaded with restraint stress. J Pharm Biomed Sci 2016;06(03):244–249.Available at www.jpbms.info
ABSTRACT
Chicken extract (CE), which is composed of water-soluble substances extracted from chicken by double boiling, could enhance mental efficiency and are helpful to the recovery from postpartum sickness and mental fatigue. But, little information is available regarding its underlying mechanisms. 5-hydroxytryptamine (5-HT), as a central neurotransmitter, involves in various functional changes of brain. In our study, we studied the effects of CE on 5-HT level in restraint-stressed mice. Male Kunming mice were randomly divided into four groups as follows: normal, restraint stress, restraint stress + 12 mL/kg/d CE (CE-L),
restraint stress + 24 mL/kg/d CE (CE-H). On the 14th day of administration, all mice were physically restrained in a 50 mL polypropylene centrifuge tube with holes for 18 h except for normal group. All mice were diethyl ether-anesthetised, 1 day after restraint stress and their brains were obtained for reverse transcription polymerase chain reaction. The levels of 5-HT in plasma, cerebral cortex and hippocampus were also determined by high performance liquid chromatography with an electrochemical detection. The results showed that CE could recover the changed levels of 5-HT in brain or plasma induced by restraint stress, the mechanism may be related to its modulation on tryptophan hydroxylase activity.
KEYWORDS chicken extract; 5-hydroxytryptamine (5-HT); restraint stress
REFERENCES
1.Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction:Implications for health. Nat Rev Immunol. 2005;5:243–251.
2.Keller SE, Schleifer SJ, Demetrikopoulos MK. Stress-induced changes in immune function in animals: hypothalamic–pituitary–adrenal influences. In: Psychoneuroimmunology. New York: Academic Press; 1991. pp. 771–784.
3.He RR, Wang M, Wang CZ, Chen BT, Lu CN, Yao XS, et al.Protective effect of apple polyphenols against stress-provoked influenza viral infection in restraint mice. J Agric Food Chem. 2011;59:3730–3737.
4.Li YF, He RR, Tsoi B, Li XD, Li WX, Abe K, et al. Anti-stress effects of carnosine on restraint-evoked immunocompromise in mice through spleen lymphocyte number maintenance. PloS one. 2012;7:e33190.
5.Elzinga BM, Bakker A, Bremner JD. Stress-induced cortisol elevations are associated with impaired delayed, but not immediate recall. Psych Res. 2005;134:211–223.
6.Payne J, Jackson ED, Ryan L, Hoscheidt S, Jacobs JW, Nadel L. The impact of stress on neutral and emotional aspects of episodic memory. Memory. 2006;14:1–16.
7.Schwabe L, Bohringer A, Chatterjee M, Schachinger H. Effects of pre-learning stress on memory for neutral, positive and negative words: different roles of cortisol and autonomic arousal. Neurobiol Learn Mem. 2008;90;44–53.
8.Cahill L, Gorski L, Le K. Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at encoding. Learn Mem. 2003;10:270–274.
9.Roozendaal B. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology. 2000;25;213–238.
10.Wolf OT. The influence of stress hormones on emotional memory: relevance for psychopathology. Acta Psychol. 2008;127:513–531.
11.Buchanan TW, Tranel D, Adolphs R. Impaired memory retrieval correlates with individual differences in cortisol response but not autonomic response. Learn Mem. 2006;13:382–387.
12.Dominique JF, Roozendaal B, McGaugh JL. Stress and glucocorticoids impair retrieval of long-term spatial memory. Nature. 1998;394:787–790.
13.Schwabe L, Wolf OT. The context counts: congruent learning and testing environments prevent memory retrieval impairment following stress. Cogn Affect Behav Neurosci. 2009;9:229–236.
14.Matsumura Y, Okui T, Ono H, Kiso Y, Tanaka T. Antihypertensive effects of chicken extract against deoxycorticosterone acetate-salt-induced hypertension in rats. Biol Pharm Bull. 2001;24:1181–1184.
15.Kurihara H, Yao XS, Nagai H, Tsuruoka N, Shibata H, Kiso Y,et al. The protective effect of brand’s essence of chicken (bec) on energy metabolic disorder in mice loaded with restraint stress. J Health Sci. 2006;52:17–23.
16.Nagai H, Harada M, Nakagawa M, Tanaka T, Gunadi B, Setiabudi MJ, et al. Effects of chicken extract on the recovery from fatigue caused by mental workload. Appl Human Sci. 1996;15:281–286.
17.Geissler C, Boroumand-Naini M,Tomassen C. Large acute thermic response to chicken essence in humans. Nutr Rep Int USA. 1989.
18.Nagai K, Suda T, Kawasaki K,Yamaguchi Y. Acceleration of metabolism of stress-related substances by l-carnosine. Nihon Seirigaku Zasshi. 1989;52:221–228.
19.Kurihara H. Correlation between changes of central neurotransmitter expression and stress response in mice a restraint timecourse analysis. Neural Regener Res. 2008;2:012.
20.McCarthy M, Nielsen D, Goldman D. Antisense oligonucleotide inhibition of tryptophan hydroxylase activity in mouse brain. Regul Pept. 1995;59:163–170.
21.Cabib S, Puglisi-Allegra S. Opposite responses of mesolimbic dopamine system to controllable and uncontrollable aversive experiences. J Neurosci. 1994;14:3333–3340.
22.Rossetti ZL, Lai M, Hmaidan Y,Gessa GL. Depletion of mesolimbic dopamine during behavioral despair: Partial reversal by chronic imipramine. Eur J Pharmacol. 1993;242:313–315.
23.Amat J, Matus-Amat P, Watkins LR, Maier SF. Escapable and inescapable stress differentially alter extracellular levels of 5-ht in the basolateral amygdala of the rat. Brain Res. 1998;812:113–120.
24.Xu C, Sim M. Effect of oral feeding of essence of chicken on the level of 5-hydroxyindoie acetic acid in the cerebrospinal fluid of the rat. Int J Food Sci Nutr. 1997;48:113–117.
25.Russo S, Kema IP, Bosker F, Haavik J, Korf J. Tryptophan as an evolutionarily conserved signal to brain serotonin: Molecular evidence and psychiatric implications. World J Biol Psychiatr.2009;10:258–268.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript. The first two authors contributed equally to the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
CLINICAL CASE
Anna Makhneva1,Yelena Kustova2*,Natalya Urazalieva3,Gulnara Abdilova4
1 Researcher, Laboratory of Pathomorphology, Almaty, Kazakhstan
2 Senior Researcher, Laboratory of Immunology, Science Center of Pediatrics and Children Surgery, Ministry of Health of the Republic of Kazakhstan, Al-Farabi av. 146, Almaty, Kazakhstan, 050040
3 Laboratory of Immunology, Almaty,Kazakhstan
4 Head of Oncogematology Department,Almaty, Kazakhstan
Address reprint requests to
*Yelena Kustova, PhD,
Researcher,Laboratory of Immunology, Science Center of Pediatrics and Children Surgery, Ministry of Health of the Republic of Kazakhstan, Al-Farabi av.146, Almaty, Kazakhstan, 050040
Article citation: Makhneva A, Kustova Y,Urazalieva N, Abdilova G. Myelofibrosis case in a child. J Pharm Biomed Sci 2016;06(03):241–243. Available at www.jpbms.info
ABSTRACT
Complexity myelofibrosis diagnosis at an early stage is that it takes place under other conditions mask: anaemia, abdominal pain, enlarged liver and spleen. This article describes
a case of myelofibrosis in a child, when the diagnosis was made late, which resulted in a poor prognosis.
KEYWORDS myelofibrosis, myeloproliferative disorders, acute myeloid leukemia
REFERENCES
1.Adamson JW, Fialkow PJ. Pathogenesis of the myeloproliferative syndromes. Br J Haematol. 1978;38:299–302.
2.Rowland B, Polsdorfer JR. Myelofibrosis. Gale Encyclopedia of Cancer, 2002. Encyclopedia.com. 10 July 2014.
3.Denham MJ. Diseases of the blood in the elderly (blood disorders in the elderly) Moscow, Medicine. 1989;352.
4.Lichtman MA. Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders.Leukemia. 2005;19(7):1139–1141.
5.Judith EK. Acute myelogenous leukemia. Humana Press.2007:426.
6.Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood.2005;105(3):973–977.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript. The first two authors contributed equally to the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.